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Soft tissue sarcomas are rare tumours with infrequent identiﬁed aetiological factors. Several genetic syndromes as well as previous
radiation therapy and/or chronic lymphoedema have been suspected to predispose to some soft tissue sarcomas. Between
January 1997 and September 2005, we carried out a prospective descriptive study to estimate the frequency of some particular
etiological factors among 658 patients with soft tissue sarcomas. Sarcomas associated with a clinically identiﬁed genetic disease
represent 2.8% out of all cases (95%CI: 1.5–3.8%). Most of these cases (14/19) are related to Recklinghausen neuroﬁbromatosis.
Radiation-induced sarcomas represent 3.3% out of all cases (95%CI: 1.7–5.1%). Most of these cases (9/22) are related to prior
breast cancer treatment. We had observed only 1 case of Stewart-Treves syndrome. Liposarcoma, the most frequent histological
subtype observed, is not associated with any particular aetiological entity. Finally, most of the adult soft tissue sarcomas are
not related to any classical clinically identiﬁed genetic disease or previous radiation therapy and/or chronic lymphoedema risk
factors. Frequency of underlying genetic syndrome which may predispose to soft tissue sarcomas could be higher than previously
reported.
Copyright © 2008 Nicolas Penel et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Soft tissue sarcomas (STS) are rare tumours. Their estimated
incidence is close to 3–4.5/100000 [1, 2]. Most of these
cancers had no clearly deﬁned cause but several infrequent
predisposing factors have been described,such as genetic
predisposition (including mainly Recklinghausen disease
and bilateral retinoblastoma) and iatrogenic factors (postir-
radiation sarcoma and postoperative chronic lymphoedema)
[1, 2]. Several previous studies have been conducted on this
topic, but have been focused on only one of these particular
risk factors. There is no recent study analyzing the frequency
of all these risk factors on the same cohort of patients. In
order to estimate the frequency of these speciﬁc factors in
adults with STS, we carried out along a 105-month period
a prospective study on all new consecutive cases treated in a
single institution located in Northern France area (4 millions
inhabitants).
2. PATIENTS AND METHODS
2.1. Patients
We have prospectively collected some clinical characteristics
ofallnewconsecutive casesofadult (over18yearsold) (STS)
treatedattheNorthernFranceComprehensiveCancercentre
(namely, Centre Oscar Lambret) between January 1997 and
September2005.Threekindsoftumourswereexcludedfrom
this study, because these cases were not (Kaposi tumours,
mixed mullerian tumours of uterus) or very recently (GIST)
treated in our institution.2 Sarcoma
Table 1: Characteristics of 658 patients with visceral and soft tissue sarcomas treated at Oscar Lambret Cancer Centre between January 1997
and September 2005. MPNST: malignant peripheral nerve sheath tumour.
Sex ratio 309 males/349 females
Age Median: 52 (18–99)
Mean: 52.4 (+/− 17.5)
Parameter Number of cases Percentage 95%-CI
Liposarcoma 132 20.0 17–23
Leiomyosarcoma 113 17.0 14–20
Malignant histiocytoﬁbroma 77 12.0 9–14
Undiﬀerentiated sarcoma 65 9.8 7–12
Synovialosarcoma 43 6.5 4–8
Aggressive ﬁbromatosis 32 4.8 3–6
Angiosarcoma 28 4.2 3–6
Rhabdomyosarcoma 26 4.0 2–5
MPNST 24 3.6 2–5
Others 118 18.0 15–20
Grade 1 97 25.2 21–30
Grade 2 101 26.3 22–30
Grade 3 186 48.4 43–53
Lower limbs 225 34.2 30–38
Chest wall 99 15.0 12–17
Upper limbs 86 13.0 9–14
Retroperitoneum 69 10.4 8–12
Head and neck 48 7.2 5–9
Uterus 41 6.2 4–8
Abdominal wall 40 6.0 4–8
Breast 30 4.5 3–6
Pelvis 13 1.9 1–3




Nationale des Centres de Lutte Contre le Cancer System [3]),
association with genetic syndrome, previous or synchronous
other malignancy, postoperative lymphoedema (Stewart-
Treves Syndrome), or postirradiation sarcoma.
A pathological review or a histological diagnosis estab-
lished in a reference centre is available in all cases (658). The
grade is available in 384 cases (58%).
2.3. Deﬁnitions
The diagnosis of genetic syndrome was based on familial
history criteria and clinical and phenotypic criteria [4–9].
For example, a patient meeting two or more of the following
criteria can be diagnosed as suﬀering from Recklinghausen’s
neuroﬁbromatosis: (i) neuroﬁbromas (two or more, or one
plexiform neuroﬁbroma), (ii) “caf´ e-au-lait” macules (six or
more measuring 1.5cm in their greatest dimension), (iii)
freckling in the axillary’s or inguinal areas, (iv) optic glioma,
(v) iris hamartomas (two or more), (vi) sphenoid dysplasia
(or thinning of the cortex of the long bones), and (vii) ﬁrst-
degree relative [4]. The other syndromes expected were: Li-
Fraumeni syndrome [5], bilateral retinoblastoma syndrome
[6], Gardner syndrome or familial polyposis adenomatous
[7], adult progeria [8], and Gorlin syndrome [9].
The diagnosis of radiation-induced sarcoma was based
on Arlen et al. [10] criteria: (i) histological diagnosis of
sarcoma, (ii) diﬀerent histological diagnosis of the previous
cancer, (iii) tumour in the border of radiation ﬁeld, and (iv)
a minimal time interval of 3 years.
2.4. Statisticalanalysis
The description of population is based on crude incidence
with 95%-conﬁdence interval for categorical parameters,
median and extreme values, or mean and standard deviation
for continuous parameters. The comparisons are based on
Fisher exact test for categorical data and Mann-Whitney test
for continuous parameters. The signiﬁcance was set up at
5%.Nicolas Penel et al. 3
Table 2: Sarcomas associated with genetic syndromes.
Sex ratio 13 males/6 females
Age Median: 37.5 (18–64)
Mean: 37.5 (+/− 14)
Parameter Number of cases Percentage 95%-CI
Recklinghausen disease 14 73.6 56–95
Bilateral retinoblastoma 2 10.5 0–23
Familial polypadenomatosis 1 5.2 0–14
Gorlin syndrome 1 5.2 0–14
Li-Fraumeni syndrome 1 5.2 0–14
MPNST 7 36.8 18–61
Undiﬀerentiated sarcoma 4 15.7 2–37
Leiomyosarcoma 2 10.5 6–30
Synovialosarcoma 2 10.5 6–30
Angiosarcoma 1 5.2 0–14
Fibrosarcoma 1 5.2 0–14
Aggressive ﬁbromatosis 1 5.2 0–14
Rhabdomyosarcoma 1 5.2 0–14
Grade 1 0 0 0–0
Grade 2 3 27.2 5–49
Grade 3 8 72.8 50–99
Chest wall 8 42.1 14–56
Lower limb 5 26.3 10–50
Head and neck 3 15.8 0–30
Abdominal wall 2 10.5 0–30




The entire population included 658 cases. The sex ratio
male/female was 309/349 (excluding uterus sarcoma, the
sex ratio was 309/308). At diagnosis, the median age was
52 (range, 18–99). The most common histological subtypes
were liposarcomas (20%), leiomyosarcomas (17%), malig-
nant ﬁbrous histiocytoﬁbromas (11%), and undiﬀerentiated
sarcomas (10%). The grade was 1 in 25% of cases, 2 in 26%,
and 3in 48%. Thetumourlocations arelisted inTable 1.The
main locations were lower limbs (34%), chest wall (15%),
upper limbs (13%), and retroperitoneum (10%).
3.2. STSassociatedwithgeneticsyndrome
Nineteen patients suﬀered from a genetic syndrome and
represented 2.8% out of all cases (IC95%: 1.5–3.8%). Most
common genetic syndromes were Recklinghausen neuroﬁ-
bromatosis (14 cases) and bilateral retinoblastoma (2 cases).
In this subpopulation, the sex ratio was 13/6 and the
median age at diagnosis was 37.5 (range, 18–64). Locations,
histological subtype, and grade are listed in Table 2.
At diagnosis, these STS associated with genetic syndrome
were signiﬁcantly younger than the entire cohort (Median
age 37.5 versus 53 years, P = .0016). In comparison with
other cases, these patients were more frequently located on
trunk (P = .002) and were more frequently peripheral mali-
gnant nerve sheath tumours (P = .005). On the contrary,
liposarcomas were signiﬁcantly less frequent in STS associ-
ated with genetic syndrome (P = .04).
3.3. Stewart-Trevessyndrome
We had observed only one case of angiosarcoma associated
with previous lymphoedema as a consequence of surgical
treatment of a previous breast cancer.
3.4. Radiation-inducedsofttissuesarcomas
Twentytworadiation-inducedSTSswereobserved.Location,
histological subtypes, and grade are listed in Table 3.T h e
mean interval from the ﬁrst cancer was 10 years (range, 3–
45 years). The most common previous cancers were breast
cancers (10 cases) and non-Hodgkin lymphomas (4 cases).
At diagnosis, the patients were signiﬁcantly older than the
entire cohort (median age 66 versus 53 years, P = .04).
In comparison with other cases, the radiation-induced were
more frequently located on chest wall (P = .002) and
were more frequently undiﬀerentiated spindle cell sarcoma
(P = .003) or angiosarcoma (P = .005). On the contrary,4 Sarcoma
Table 3: Radiation-induced sarcomas.
Sex ratio 5 males /17 females
Age Median: 6 (27–83)
Mean: 57 (+/− 17)
Parameter Number of cases Percentage 95%-CI
Previous cancer — — —
Breast cancer 10 45.0 24–66
Lymphoma 4 18.2 0–28
Cervix cancer 2 9.0 0–20
Prostate cancer 1 4.5 0–13
Bilateral retinoblastoma 1 3.5 0–13
Uterus cancer 1 4.5 0–13
Meningioma 1 4.5 0–13
Lymphoblastic acutate leukemia 1 4.5 0–13
Head and neck 1 4.5 0–13
Undiﬀerentiated spindle cell sarcoma 11 50.0 24–66
Angiosarcoma 4 18.2 2–34
Leiomyosarcoma 2 9.0 0–20
Osteosarcoma 1 4.5 0–13
Chondrosarcoma 1 4.5 0–13
Liposarcoma 1 4.5 0–13
PNET 1 4.5 0–13
Malignant hemangioendothelioma 1 4.5 0–13
Grade 1 1 5.5 0–13
Grade 2 2 11.1 0–29
Grade 3 15 83.3 72–100
Chest wall 10 45.4 14–66
Head and neck 4 18.2 5–40
Lower limb 2 9.0 0–20
Upper limb 2 9.0 0–20
Pelvis 2 9.0 0–20
Retroperitoneum 1 4.5 0–20
Uterus 1 4.5 0–13
liposarcomas were signiﬁcantly less frequent in radiation-
induced sarcoma group (P<. 001).
4. DISCUSSION
In this prospective study of 658 adult STS, about 6% of
patients present a well-established risk factor: a genetic
syndrome (2.8%) or an iatrogenic factor such as previous
radiation therapy (3.3%) or a postoperative chronic lym-
phoedema (1 case). The characteristics of our entire group
of patients are consistent literature; the sex ratio is closed to
1[ 1, 2], the median age is 55 years [1], lower and upper
limbs locations are the most frequent, liposarcomas and
leiomyosarcoma are the most common histological subtypes
(after excluding malignant ﬁbrous histiocytoﬁbroma), and
grade 3 tumours are the most frequent [11, 12].
Twenty two cases out of 658 (3.3%, 95% CsI: 1.7–5.1%)
present a radiation-induced STS. In longitudinal studies, the
prevalence of radiation-induced sarcomas is very low, close
to 0.14–0.20% [13–15]. After treatment by radiotherapy,
the relative risk for development of STS is comprised
b e t w e e n8a n d5 0[ 10, 13, 14]. As previously published
[16], in our series, breast cancers and lymphomas were
the most frequent previous primaries treated with radiation
therapy. Radiation-induced sarcomas are more frequently
STS (70%) than osseous sarcomas (30%) [16]. Malignant
ﬁbrous histiocytoﬁbromas (16% in the Brady et al. series)
and angiosarcomas (15%) are the most common histological
subtype of radiation-induced STS. The liposarcomas are
exceptional[16].IntheWeissandEnzingerseries,about10%
ofangiosarcomas are radio-induced [17]. Radiation-induced
STS are usually high-grade tumours, for example, in the
Brady’s series, less than 6% of radio-induced sarcomas are
grade 1 [18]. The radiation-induced sarcomas are usually
developed at the peripheral borders of radiation ﬁelds. The
mean interval from the ﬁrst cancer treatment is about 10Nicolas Penel et al. 5
years (range, 2 and 67 years) [10, 13–16]. Angiosarcomas
seem occur after a shorter interval (about 5 years) [10, 13–
15]. The interval is also shorter in cases associated with
Bilateral Retinoblastoma [6].
The Stewart-Treves syndrome is deﬁned as the develop-
ment of angiosarcoma or lymphangiosarcoma on chronic
lymphoedema whatever its cause (congenital, postsurgical,
orcausedbyﬁlariosis,...)[18].TheStewart-Trevessyndrome
is exceptional and about 300 cases are known in literature.
Mostofcases(168/186)areobservedafteraxillary’sclearance
for breast cancer [19]. In the Connecticut Registry, 8 cases
are diagnosed after the treatment of more than 41000 breast
cancers [20]. The mean interval is about 10 years (4–27)
for cases secondary to breast cancer treatment [18, 19, 21].
The Stewart-Treves syndrome represents about 5% of all
angiosarcomas [18, 19, 21].
In contrast to literature that describes STS are classically
related to genetic syndromes in less than 1% [1] this study
shows that 2.8% [1.5–3.8] of our patients suﬀered from a
clinically-diagnosed genetic syndrome. Recklinghausen neu-
roﬁbromatosis and bilateral retinoblastoma predominate.
Other genetic syndromes (Li-Fraumeni syndrome, Gardner
syndrome, ataxia-telangiectasia, and progeria) appear excep-
tional. We had no clear explanation to the present higher
than previously described frequency of genetic syndrome.
The estimated incidence of Recklinghausen Neuroﬁbro-
matosis is about 1/3,000–1/5,000. Fifty percent of cases
are sporadic [4, 20] .T h e s ep a t i e n t sh a dar e l a t i v er i s ko f
cancers (including STS and other sarcomas) about 4 in
comparison with general population [4, 20]. Cancers are
the ﬁrst cause of precocious deaths in such population.
About 5% of patients aﬀected by Recklinghausen Neu-
roﬁbromatosis develop malignant peripheral nerve sheath
tumour (MPNST). The MPNST are usually developed
on a neuroﬁbroma [4, 22] and can be multiple [4, 22].
The male predominance is well established (sex ratio 4/1
[23]). The median age at diagnosis of STS is about 32–
36, clearly inferior to age diagnosis in general population
[22, 23]. Classically, about 40% of MPNST is associated with
Recklinghausen Neuroﬁbromatosis [23]. In our experience,
8 out of 24 MPNST are associated with Recklinghausen
Neuroﬁbromatosis. The prognosis of MPNST is not inﬂu-
enced by the presence of Recklinghausen Neuroﬁbromatosis;
the 5-year overall survival is about 40% [23]. In our study,
all ﬁndings are consistent with the literature data (male
predominance, young age, mainly MPNST).
The present study presents several limitations. Firstly,
our study is not exhaustive; because according to estimated
incidence (3–4.4/100000) [1, 2]o fa d u l tS T Si nW e s t e r n
countries, a total number comprised between 1140 and 1670
cases are expected in our region in the same period. In
consequence, we estimate that our cohort represent between
44% and 65% of all cases. Secondly, it is a single-centre
study and our results may not be directly applicable to other
areasinFranceorabroad.Themalignantnatureofaggressive
ﬁbromatosis is still debated, but more recent reports suggest
that a part of these tumours must be considered as a
particular form of low-grade ﬁbrosarcoma [24, 25]. Because
ofrecentprogressinhistology,theproportionofthediﬀerent
histological subtypes must be considered with caution. For
example, the “malignant ﬁbrous histiocytoﬁbroma” actually
disappears and this diagnosis is modiﬁed into dediﬀerenti-
ated liposarcoma and dediﬀerentiated leiomyosarcoma [26].
Moreover, the diagnosis of genetic syndromes were based
on clinical criteria, a systematic genetic testing can possibly
modify those results.
4.1. Conclusion
Most cases of adult STS (94% in our experience) are not
related to well-established risk factors (radiation, genetic
disease, and chronic lymphedema). Liposarcoma is the most
frequent histological subtype, but it is rarely associated
with genetic disease or postirradiation. New epidemiological
explorations are necessary to analyze, for example, the
environmentalandoccupationalriskfactors(suchasarsenic,
phenoxy-herbicides) and new iatrogenic factors (such as
new chemotherapy agents and new techniques of radiation
therapy) [27–29].
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